Asia · Markets & Finance · Vietnam Investment Review

China approves Jaypirca for chronic lymphocytic leukaemia treatment indications

Published by Vietnam Investment Review · Vietnam 11 h ago

Healthcare regulator National Medical Products Administration approved Innovent Biologics' drug Jaypirca for treating chronic lymphocytic leukaemia and small lymphocytic lymphoma…

Read the full article on Vietnam Investment Review Sign in to save

MediaNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (vir.com.vn)

Also worth reading

The Straits Times Business

DFI to take control of Starbucks in Asia, to give up F&B brands including Genki Sushi, Shake Shack

CNBC-TV18

Top stocks in focus tomorrow: Investors must watch Jio Financial, Infosys, NCC shares on Thu, 1 Oct | Triggers

Business Standard

China approves Jaypirca for chronic lymphocytic leukaemia treatment indications

Share

Also worth reading

DFI to take control of Starbucks in Asia, to give up F&B brands including Genki Sushi, Shake Shack

Stocks to Watch for October 1: Insurance stocks, IRFC, NCC, Infosys and more

New World Development posts HK$26.8b loss after 11 Skies termination

Vadilal resets after 10 years & amid a family battle

Top stocks in focus tomorrow: Investors must watch Jio Financial, Infosys, NCC shares on Thu, 1 Oct | Triggers

Reliance Industries raises ₹13,000 crore through 10-year bonds at 7.90%